## Claims

## 1. A compound of formula I

**(I)** 

or a pharmaceutically acceptable salt thereof; wherein R1 is H, methyl or ethyl; R2 is H or phenyl and

B is

4)

- 1) -(CH<sub>2</sub>)<sub>3</sub>NHC(NH)NH<sub>2</sub>,
- 2) -(CH<sub>2</sub>)<sub>3</sub>NH<sub>2</sub>,
- 3) -(CH<sub>2</sub>)<sub>2</sub>NH<sub>2</sub> or

5

10

15

wherein asterisk (\*) indicates the point of attachment; with the proviso that when B is  $-(CH_2)_3NHC(NH)NH_2$ , then R1 is not hydrogen.

## 2. A compound of claim 1 whereby the compound has the structure

3. A compound of claim 1 whereby the compound has the structure

4. A compound of claim 1 whereby the compound has the structure

5. A compound of claim 1 whereby the compound has the structure

6. A compound of claim 1 whereby the compound has the structure

10

5

7. A compound of claim 1 whereby the compound has the structure

$$H_2N \longrightarrow S \qquad N \longrightarrow S \qquad 0$$

$$N \longrightarrow S \qquad 0$$

8. A compound of claim 1 whereby the compound has the structure

5

9. A compound of claim 1 whereby the compound has the structure

10

10. A pharmaceutical composition comprising of a compound according to any of claims 1 to 9 as an active ingredient together with a pharmaceutically acceptable diluent, carrier and/or excipient.

ti 15 a

11. The use of a compound of any of claims 1 to 9, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for treating a disease or condition in mammals where interaction with the somatostatin receptor subtype 4 optionally together with the subtype 1 is indicated to be useful.